# Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

> **NCT05607420** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cellectis S.A.** · enrollment: 80 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma (B-NHL)

## Interventions

- **BIOLOGICAL:** UCART20x22
- **BIOLOGICAL:** CLLS52

## Key facts

- **NCT ID:** NCT05607420
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607420, "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05607420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*